

Contents

1	Introduction	1
1.1	Background	1
1.2	Polymorphism	3
1.3	Multi-component Crystalline Systems: Solvates, Salts and Co-crystals	4
1.4	Amorphous Solids	6
1.5	Importance of Solid-State Form for Pharmaceutical Industry	6
1.6	Crystallisation	7
1.7	Crystallisation Techniques	8
1.8	Control of Solid Form	10
1.9	Computational Methods	13
1.9.1	Crystal Structure Prediction	13
1.9.2	Energetics of Non-bonded Interactions: The PIXEL/Semi-classical Density Sums Methods	16
1.10	Experimental and Computational Studies on Structurally Related Compounds	18
	References	23
2	Aims and Objectives	29
2.1	Aims	29
2.2	Objectives	30
3	Materials and Methods	31
3.1	Material	31
3.2	Methods	31
3.2.1	Crystallisation Techniques	31
3.2.2	X-Ray Crystallography	33
3.2.3	Thermal Analysis	35
3.2.4	Raman and Infrared Spectroscopy	35
3.2.5	PIXEL Calculations	35
3.2.6	Crystal Packing Analysis	36
	References	36

4	Development and Validation of High-Throughput Crystallisation and Analysis (HTCAA) Methodology for Physical Form Screening	39
4.1	Introduction	39
4.2	Sample Preparation and Methodology Development	45
4.2.1	96/48 Quartz Multi-well Plate	45
4.2.2	Preparation of 96-Well Plate for Salt Screening of Amoxapine	46
4.2.3	Preparation of 48-Well Plate for Physical Form Screening of Clozapine	47
4.2.4	Preparation of 96-Well Plate for Physical Form Screening of Olanzapine	47
4.2.5	Raman Microscopy	49
4.2.6	Chemometric Analysis	50
4.2.7	Scale-up and Characterisation of Novel Forms	51
4.3	Results and Discussion	52
4.3.1	Salt Screening of Amoxapine	52
4.3.2	Physical Form Screening of Clozapine	60
4.3.3	Physical Form Screening of Olanzapine	65
4.4	Key Findings of the Developed HTCAA Methodology	70
4.5	Summary	73
	References	74
5	Predicting Crystallisability of Organic Molecules Using Statistical Modelling Techniques	77
5.1	Statistical Modelling Techniques	77
5.1.1	Introduction	77
5.1.2	Principal Component Analysis	78
5.1.3	Criteria for Deciding the Number of Principal Components	79
5.1.4	Random Forests Classification Method	80
5.1.5	Applications of Statistical Modelling Techniques in Pharmaceutical Industry	82
5.2	Descriptor Calculations, Model Building and Validation	86
5.2.1	Training Dataset and 2- and 3-Dimensional Descriptors Calculations	86
5.2.2	Training the Statistical Model	88
5.3	Results and Discussion	88
5.3.1	Principal Component Analysis	88
5.3.2	Random Forests Classification Model	89
5.3.3	Model Optimisation Attempts	91
5.3.4	Important Descriptors Assessment	93
5.3.5	Limitations of Random Forests Classification Model	94
5.4	Summary	95
	References	95

6	Exploring the Crystal Structure Landscape of Olanzapine	99
6.1	Introduction.	99
6.2	Experimental Procedures.	102
6.2.1	Crystallisation	102
6.2.2	Variable Temperature-X-Ray Powder Diffraction	105
6.2.3	XPac Analysis of Crystal Structures of Olanzapine.	105
6.2.4	Random Forests Classification Model of Olanzapine Solvates	106
6.3	Calculation and Analysis of the Crystal Energy Landscape (Crystal Structure Prediction) of Olanzapine	106
6.4	Results and Discussion	109
6.4.1	Forms I, II and III of Olanzapine	109
6.4.2	Solution Crystallisation of Olanzapine	112
6.4.3	Neat and Liquid-Assisted Grinding of Olanzapine	118
6.4.4	Desolvation of Olanzapine Solvates	120
6.4.5	Melt Quenching and Recrystallisation of Amorphous Olanzapine	120
6.4.6	Spray Drying and Freeze Drying of Olanzapine	123
6.5	Molecular Packing Analysis of Olanzapine Crystal Structures Using XPac.	123
6.6	Hydrogen-Bonding Analysis of Olanzapine Crystal Structures	127
6.6.1	Hydrogen Bonding in Olanzapine Solvates Based on Packing Type SC ₃₁	129
6.6.2	Hydrogen Bonding in Olanzapine Solvates Based on Packing Type SC ₃₂	129
6.6.3	Hydrogen Bonding in Olanzapine Solvates Based on Packing Type, SC ₃₃	130
6.6.4	Hydrogen Bonding in Other Olanzapine Solvates Based on SC ₀ , SC ₁₁ and SC ₂₂	131
6.7	Prediction of Olanzapine Solvate Formation Using Random Forests Classification Model	132
6.7.1	Random Forests Classification Model – Prediction Results	132
6.7.2	Important Solvent Physicochemical Descriptors for Random Forests Classification Model of Olanzapine Solvates	136
6.8	Crystal Energy Landscape of Olanzapine	138
6.9	PIXEL Calculations on Olanzapine	141
6.10	Concomitant Appearance of Form III with Other Polymorphs of Olanzapine	144
6.11	Prolific Solvate Formation of Olanzapine	145

6.12	Challenges with Crystal Structure Prediction of Olanzapine and Unobserved Calculated Structures	146
6.13	Summary	147
	References	148
7	Exploring the Physical Form Landscape of Clozapine, Amoxapine and Loxapine.	153
7.1	Introduction.	153
7.1.1	Background of Molecule in Group 1-Clozapine	154
7.1.2	Background of Molecules in Group 2-Amoxapine and Loxapine.	154
7.2	Experimental Details	155
7.2.1	Principal Component Analysis of Solvent Properties.	155
7.2.2	Crystallisation Experiments of Clozapine	155
7.2.3	Crystallisation Experiments of Amoxapine	155
7.2.4	Crystallisation Experiments of Loxapine	156
7.2.5	Preliminary Crystal Structure Prediction Studies for Clozapine, Amoxapine and Loxapine.	158
7.2.6	Solid-State Calculations Using CASTEP.	158
7.2.7	Structure Analysis	159
7.3	Results and Discussion	159
7.3.1	Physical Form Screening of Clozapine	159
7.3.2	Physical Form Screening Results of Amoxapine.	173
7.3.3	Physical Form Screening Results of Loxapine	178
7.4	Summary	190
	References	191
8	Conclusions and Further Work	195
8.1	Conclusions and Further Work	195
8.1.1	Development and Validation of High Throughput Crystallisation and Analysis Methodology for Physical Form Screening	198
8.1.2	Predicting Crystallisability of Organic Molecules Using Statistical Modelling Techniques.	198
8.1.3	Exploring the Physical Form Landscape of Structurally Related Pharmaceutical Molecules in Group 1 (Olanzapine and Clozapine) and 2 (Amoxapine and Loxapine)	199
8.2	Further Work	201
8.2.1	Development and Validation of High Throughput Crystallisation and Analysis Methodology for Physical Form Screening	201
8.2.2	Predicting Crystallisability of Organic Molecules Using Statistical Modelling Techniques.	202

8.2.3	Exploring the Physical Form Landscape of Structurally Related Pharmaceutical Molecules in Group 1 (Olanzapine and Clozapine) and 2 (Amoxapine and Loxapine)	203
	References	204
Appendix	207



<http://www.springer.com/978-3-319-27554-3>

Control and Prediction of Solid-State of
Pharmaceuticals
Experimental and Computational Approaches
Bhardwaj, R.M.
2016, XXXVII, 238 p. 121 illus., 77 illus. in color.,
Hardcover
ISBN: 978-3-319-27554-3